FDA Pulls Fast-Track Designation for Tonix’s PTSD Treatment

Drug Industry Daily
A A
The FDA revoked its breakthrough therapy designation for Tonix’s posttraumatic stress disorder drug Tonmya (cyclobenzaprine HCl sublingual tablets), citing disappointing interim data from a clinical trial.

To View This Article:

Login

Subscribe To Drug Industry Daily